Daniel J. Tenney

5.6k total citations · 2 hit papers
63 papers, 4.2k citations indexed

About

Daniel J. Tenney is a scholar working on Epidemiology, Hepatology and Immunology. According to data from OpenAlex, Daniel J. Tenney has authored 63 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Epidemiology, 20 papers in Hepatology and 14 papers in Immunology. Recurrent topics in Daniel J. Tenney's work include Hepatitis B Virus Studies (23 papers), Herpesvirus Infections and Treatments (22 papers) and Hepatitis C virus research (18 papers). Daniel J. Tenney is often cited by papers focused on Hepatitis B Virus Studies (23 papers), Herpesvirus Infections and Treatments (22 papers) and Hepatitis C virus research (18 papers). Daniel J. Tenney collaborates with scholars based in United States, Germany and Italy. Daniel J. Tenney's co-authors include Richard J. Colonno, Kevin A. Pokornowski, Anamaris M. Colberg‐Poley, Carl J. Baldick, Ronald E. Rose, Betsy J. Eggers, Jie Fang, Ann W. Walsh, Steven M. LeVine and Amy K. Sheaffer and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Daniel J. Tenney

62 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #

2009 607 citations Daniel J. Tenney, Ronald E. Rose et al. Hepatology profile →
Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B

2010 444 citations Ting‐Tsung Chang, Ching‐Lung Lai et al. Hepatology profile →

Peers

Countries citing papers authored by Daniel J. Tenney

Since Specialization

Citations

This map shows the geographic impact of Daniel J. Tenney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Tenney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Tenney more than expected).

Fields of papers citing papers by Daniel J. Tenney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Tenney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Tenney. The network helps show where Daniel J. Tenney may publish in the future.

Co-authorship network of co-authors of Daniel J. Tenney

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Tenney. A scholar is included among the top collaborators of Daniel J. Tenney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Tenney. Daniel J. Tenney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma 2024 ·Clinical Cancer Research ·(unknown), Robert Ferguson, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sonia Dolfi, Daniel J. Tenney, Yongzhao Shao, Iman Osman, Jeffrey S. Weber, Tomas Kirchhoff	2
2	Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K). 2023 ·Journal of Clinical Oncology ·Georgina V. Long, John M. Kirkwood, Christoph Höeller, Jean‐Jacques Grob, Jeffrey S. Weber, Janis M. Taube, Peter Mohr, Alexander Christopher Jonathan Van Akkooi, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion‐Sileni, Daniel J. Tenney, Sonia Dolfi, Hao Tang, Corey Ritchings, Maurice Lobo, Federico Campigotto, Wenjia Wang, Brian Gastman, Michele Del Vecchio	8
3	Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238. 2023 ·Journal of Clinical Oncology ·(unknown), Jennifer Wiggins, (unknown), (unknown), Hao Tang, (unknown), (unknown), Keyur Desai, Sonia Dolfi, Daniel J. Tenney, Paolo A. Ascierto, James Larkin, Michele Del Vecchio, Jeffrey S. Weber, David Polsky	3
4	Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma 2023 ·Cancer Cell ·Katie M. Campbell, (unknown), Shannon M. Pfeiffer, Timothy R. Howes, Egmidio Medina, Michael J. Travers, Gabriela Steiner, Jeffrey S. Weber, Jedd D. Wolchok, James Larkin, F. Stephen Hodi, Silvia Boffo, Lisa Salvador, Daniel J. Tenney, Tracy Tang, (unknown), Christine N. Spencer, Daniel K. Wells, Antoni Ribas	50
5	Development, Characterization, and Radiation Dosimetry Studies of 18F-BMS-986229, a 18F-Labeled PD-L1 Macrocyclic Peptide PET Tracer 2023 ·Molecular Imaging and Biology ·(unknown), David J. Donnelly, (unknown), (unknown), (unknown), (unknown), Yunhui Zhang, (unknown), Paul M. Scola, Daniel J. Tenney, Michael A. Poss, Matthew G. Soars, Samuel J. Bonacorsi, Erin L. Cole, Diederik J. Grootendorst, Patrick L Chow, Nicholas A. Meanwell, Shuyan Du	3
6	High-Throughput Screening and Rapid Inhibitor Triage Using an Infectious Chimeric Hepatitis C Virus 2012 ·PLoS ONE ·Michael Wichroski, Jie Fang, Betsy J. Eggers, Ronald E. Rose, Charles E. Mazzucco, Kevin A. Pokornowski, Carl J. Baldick, (unknown), (unknown), Lauren E. Barber, John E. Leet, Brett R. Beno, Samuel W. Gerritz, (unknown), Mark I. Cockett, Daniel J. Tenney	8
7	Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B breakdown → 2010 ·Hepatology ·Ting‐Tsung Chang, Ching‐Lung Lai, Seung Kew Yoon, Samuel S. Lee, Henrique Sérgio Moraes Coelho, Flair José Carrilho, Fred Poordad, Waldemar Halota, Yves Horsmans, Naoky Tsai, Hui Zhang, Daniel J. Tenney, Ricardo Tamez, Uchenna H. Iloeje	444
8	Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies 2010 ·Antiviral Therapy ·Daniel J. Tenney	13
9	Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy # breakdown → 2009 ·Hepatology ·Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick, Kevin A. Pokornowski, Betsy J. Eggers, Jie Fang, Michael Wichroski, Dong Xu, Joanna Yang, Richard B. Wilber, Richard J. Colonno	607
10	Entecavir therapy for lamivudine‐refractory chronic hepatitis B 2008 ·Hepatology ·Morris Sherman, Cihan Yurdaydın, Halis Şimşek, Marcelo José Barbosa Silva, Yun‐Fan Liaw, Vinod K. Rustgi, Hoel Sette, Naoky Tsai, Daniel J. Tenney, (unknown), Bruce Kreter, R. Hindes	133
11	Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy 2008 ·Journal of Hepatology ·Daniel Shouval, Ching‐Lung Lai, Ting‐Tsung Chang, Hugo Cheinquer, Paul Martin, Giampiero Carosi, Steven Han, Sabahattin Kaymakoğlu, Ricardo Tamez, Joanna Yang, Daniel J. Tenney, H. Brett‐Smith	83
12	Entecavir resistance is rare in nucleoside naïve patients with hepatitis B 2006 ·Hepatology ·Richard J. Colonno, Ronald E. Rose, Carl J. Baldick, Steven M. LeVine, Kevin A. Pokornowski, Cheng Fang Yu, Ann W. Walsh, Jie Fang, Mayla Hsu, Charles E. Mazzucco, Betsy J. Eggers, Sharon Zhang, Mary Jane Plym, K. Klesczewski, Daniel J. Tenney	276
13	The human cytomegalovirus UL98 gene encodes the conserved herpesvirus alkaline nuclease. 1997 ·Journal of General Virology ·Amy K. Sheaffer, Steven P. Weinheimer, Daniel J. Tenney	27
14	Sequence-dependent Primer Synthesis by the Herpes Simplex Virus Helicase-Primase Complex 1995 ·Journal of Biological Chemistry ·Daniel J. Tenney, Amy K. Sheaffer, Warren Hurlburt, Marc Bifano, Robert Hamatake	23
15	Characterization of monoclonal antibodies recognizing amino- and carboxy-terminal epitopes of the herpes simplex virus UL42 protein 1995 ·Virus Research ·Amy K. Sheaffer, Warren Hurlburt, John T. Stevens, Marc Bifano, Robert Hamatake, Richard J. Colonno, Daniel J. Tenney	7
16	The human cytomegalovirus US3 immediate-early protein lacking the putative transmembrane domain regulates gene expression 1993 ·Nucleic Acids Research ·Daniel J. Tenney, Linda D. Santomenna, (unknown), Anamaris M. Colberg‐Poley	34
17	Expression of the human cytomegalovirus UL36–38 immediate early region during permissive infection 1991 ·Virology ·Daniel J. Tenney, Anamaris M. Colberg‐Poley	76
18	Differentiation of the U937 Macrophage Cell Line Removes an Early Block of HSV-1 Infection 1991 ·Viral Immunology ·Daniel J. Tenney, Page S. Morahan	15
19	RNA Analysis and Isolation of cDNAs Derived from the Human Cytomegalovirus Immediate-Early Region at 0.24 Map Units 1990 ·Intervirology ·Daniel J. Tenney, Anamaris M. Colberg‐Poley	21
20	Effect of Macrophage Activation on Resistance of Mouse Peritoneal Macrophages to Infection with Herpes Simplex Virus Types 1 and 2 1988 ·Journal of General Virology ·(unknown), Daniel J. Tenney, Jay L. Rothstein, Page S. Morahan	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact